日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients

前瞻性随机HOVON-103试验中老年AML患者外部对照患者和内部对照患者的可比性

Hermans, Sjoerd J F; Versluis, Jurjen; van Werkhoven, Erik D; van Norden, Yvette; Janssen, Jeroen J W M; Huls, Gerwin A; Pabst, Thomas; Breems, Dimitri A; Berkx, Elizabeth; Dinmohamed, Avinash G; Huijgens, Peter C; Sträng, Eric; Hernández Rivas, Jesús María; Sobas, Marta; Ayala Diaz, Rosa; Martinez Lopez, Joaquin; Metzeler, Klaus H; Haferlach, Torsten; Thiede, Christian; Uyl-de Groot, Carin A; Bullinger, Lars; Löwenberg, Bob; Ossenkoppele, Gert J; Pignatti, Francesco; Cornelissen, Jan J

CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents

CD34+CD38-白血病干细胞可预测接受非强化低甲基化药物治疗的急性髓系白血病患者的临床结局。

Reuvekamp, Tom; Ngai, Lok Lam; den Hartog, Daphne; Carbaat-Ham, Jannemieke; Fayed, Mona M H E; Scholten, Willemijn J; Mocking, Tim R; Chitu, Dana A; Pabst, Thomas; Klein, Saskia K; Stussi, Georg; Griskevicius, Laimonas; Breems, Dimitri; van Lammeren-Venema, Danielle; Boersma, Rinske; Ossenkoppele, Gert J; van de Loosdrecht, Arjan A; Bachas, Costa; Huls, Gerwin; de Leeuw, David C; Cloos, Jacqueline

Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial

急性髓系白血病中可计算的残留病灶评估:HOVON-SAKK-132 试验的回顾性验证

Mocking, Tim R; Haaksma, Lukas H; Reuvekamp, Tom; Kelder, Angèle; Scholten, Willemijn J; Ngai, Lok Lam; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjørn T; Griškevičius, Laimonas; Juliusson, Gunnar; Maertens, Johan A; Manz, Markus G; Pabst, Thomas; Passweg, Jakob R; Porkka, Kimmo; Valk, Peter J M; Gradowska, Patrycja; Löwenberg, Bob; de Leeuw, David C; Janssen, Jeroen J W M; Ossenkoppele, Gert J; van de Loosdrecht, Arjan A; Cloos, Jacqueline; Bachas, Costa

Different features of acute myeloid leukemia stem cell quantification in intensively treated patients

接受强化治疗的急性髓系白血病患者中急性髓系白血病干细胞定量分析的不同特征

Ngai, Lok Lam; Reuvekamp, Tom; Hanekamp, Diana; Janssen, Fleur; Marsbergen, Laura Oudshoorn-van; Carbaat-Ham, Jannemieke; Hofland, Maaike A M; Fayed, Mona M H E; Kelder, Angèle; Scholten, Willemijn J; Snel, Alexander N; Bachas, Costa; Tettero, Jesse M; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjørn T; Griškevičius, Laimonas; Juliusson, Gunnar; Van de Loosdrecht, Arjan A; Maertens, Johan A; Manz, Markus G; Pabst, Thomas; Passweg, Jakob R; Porkka, Kimmo; Valk, Peter J M; Gradowska, Patrycja; Löwenberg, Bob; Ossenkoppele, Gert J; De Leeuw, David C; Cloos, Jacqueline

A revised prognostic model for patients with acute myeloid leukemia and first relapse

急性髓系白血病首次复发患者的修订预后模型

van der Maas, Niek G; Breems, Dimitri; Klerk, Clara P W; Pabst, Thomas; Gradowska, Patrycja; Thomas, Abin; Biemond, Bart J; Kuball, Jurgen; Van Elssen, Catharina H M J; Visser, Otto; Vekemans, Marie-Christiane; Graux, Carlos; Maertens, Johan; Knapper, Steven; Dennis, Mike; Freeman, Sylvie; Thomas, Ian; Beverloo, H Berna; Huls, Gerwin; Craddock, Charles; Valk, Peter J M; Vyas, Paresh; Russell, Nigel; Ossenkoppele, Gert; Löwenberg, Bob; Cornelissen, Jan J; Versluis, Jurjen

Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane

HOVON 170 DLBCL-ANTICIPATE试验的原理和设计:使用右雷佐生预防蒽环类药物引起的心脏功能障碍

Linschoten, Marijke; Geels, Jesse; van Werkhoven, Erik; Visser-Wisselaar, Heleen; Chamuleau, Martine E D; Teske, Arco J; Robbers, Lourens; Oerlemans, Simone; Crommelin, Heleen; Breems-de Ridder, Marleen; Schut, Astrid; Asselbergs, Folkert W; van Rhenen, Anna

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome

对于不适合接受强化化疗的急性髓系白血病 (AML) 和高危骨髓增生异常综合征 (MDS) 患者,无论 FLT3 突变状态如何,在 10 天地西他滨疗程中加入米哚妥林并不能改善预后。

Huls, Gerwin; Chitu, Dana A; Tick, Lidwine; Boersma, Rinske; Breems, Dimitri; Herbers, Alexandra; Klein, Saskia K; de Jonge, Suzan; Westerweel, Peter E; Cruijsen, Marjan; Hoogendoorn, Mels; Cuijpers, Marlous; Deeren, Dries; Bailly, Benjamin; Visser, Otto; van Rhenen, Anna; Posthuma, Eduard F M; Valk, Peter J M; Cloos, Jacqueline; Ammatuna, Emanuele; Refos, Jeannine M; Fakkert, R; Löwenberg, Bob; Ossenkoppele, Gert J

Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial

前瞻性随机研究的贝叶斯中期分析:急性髓系白血病 HOVON 132 临床试验的再分析

van der Maas, Niek G; Versluis, Jurjen; Nasserinejad, Kazem; van Rosmalen, Joost; Pabst, Thomas; Maertens, Johan; Breems, Dimitri; Manz, Markus; Cloos, Jacqueline; Ossenkoppele, Gert J; Floisand, Yngvar; Gradowska, Patrycja; Löwenberg, Bob; Huls, Gerwin; Postmus, Douwe; Pignatti, Francesco; Cornelissen, Jan J

Real-world insights on the management of immune-mediated thrombotic thrombocytopenic purpura with caplacizumab

卡普拉西珠单抗治疗免疫介导的血栓性血小板减少性紫癜的真实世界疗效

Dierickx, Daan; Connerotte, Thierry; Dallemagne, Julie; De Becker, Ann; Moors, Ine; Snauwaert, Sylvia; Sonet, Anne; Theunissen, Koen; Breems, Dimitri; De Voeght, Adrien; Jaspers, Aurélie; Lambert, Catherine; Heyrman, Bert; Hautekiet, Joris; Lyna, Sofie; Maertens, Chantal; Delrieu, Vanessa

Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial

HOVON-SAKK132试验中CD34+CD38- AML干细胞频率预后相关性的前瞻性验证

Ngai, Lok Lam; Hanekamp, Diana; Janssen, Fleur; Carbaat-Ham, Jannemieke; Hofland, Maaike A M A; Fayed, Mona M H E; Kelder, Angèle; Oudshoorn-van Marsbergen, Laura; Scholten, Willemijn J; Snel, Alexander N; Bachas, Costa; Tettero, Jesse M; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjørn T; Griškevičius, Laimonas; Juliusson, Gunnar; van de Loosdrecht, Arjan A; Maertens, Johan A; Manz, Markus G; Pabst, Thomas; Passweg, Jakob R; Porkka, Kimmo; Valk, Peter J M; Gradowska, Patrycja; Löwenberg, Bob; de Leeuw, David C; Janssen, Jeroen J W M; Ossenkoppele, Gert J; Cloos, Jacqueline